<DOC>
	<DOCNO>NCT00767377</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability combination epirubicin , oxaliplatin 5-day continuous infusional 5-fluorouracil ( EOF5 regimen ) patient unresectable advanced metastatic gastric cancer ( A/MGC ) . Since Mar 2011 , two addition second endpoint add trial , one compare consistence two type PET Scan evaluation routine CT Scan evaluation , search predictor factor clinical result ( ORR , PFS OS ) Pharmacogenomics method . This modification approve Ethic Committee Fudan University Cancer Hospital , approval number IRB50-15-1101A .</brief_summary>
	<brief_title>Continuous Infusion FU Combined With Epirubicin Oxaliplatin Patients With A/MGC</brief_title>
	<detailed_description>ECF regimen consider reference regimen gastric cancer Europe . Now , regimen prove effective less toxicity ECF regimen . Oxaliplatin demonstrate synergy 5-FU vitro , vivo , clinical setting advance colorectal cancer . It present well toxicity profile cisplatin . Recently study use combination regimen oxaliplatin , folinic acid , continuous infusion 5-FU 44 hour ( e.g FOLFOX4 ) treat A/MGC , yield good response rate median overall survival time result low rate grade 3-4 adverse event . Therefore , logical modify ECF regimen oxaliplatin replace cisplatin short-term FU infusion replace 21-day FU infusion . Our objective evaluate whether EOF5 regimen less toxicity comparable effective ECF regimen .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically confirm advanced metastatic adenocarcinoma stomach ECOG performance scale ≤2 At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Adequate hepatic , renal , heart , hematologic function ( platelet ＞80×109/L , neutrophil＞2.0×109/L , serum creatinine ≤1.5mg/dl , total bilirubin within upper limit normal ( ULN ) , serum transaminase≤2.5×the ULN ) Pregnant lactate woman Concurrent cancer History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Neuropathy , brain , leptomeningeal involvement Clinically relevant coronary artery disease history myocardial infarction within last 12 month high risk/uncontrolled arrhythmia Uncontrolled significant comorbid condition previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Time Progression</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Response rate</keyword>
	<keyword>Quality Live</keyword>
	<keyword>Toxicities</keyword>
</DOC>